Subsequently, they enrolled 77 patients with NSCLC and found that platelets can be used for the non-invasive detection of EML4-ALK rearrangements in these patients predicting the outcome of the therapy (35). The gene discussed is ALK; the disease is non-small cell lung carcinoma.